Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Controlled, Open-Label Clinical Trial With Blinded Endpoint Assessment of Prophylactic Rituximab for Reducing Clinically Significant EBV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT07703657 is registered in ClinicalTrials.gov with Yang Donglin as lead sponsor.

NCT NCT07703657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07703657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Controlled, Open-Label Clinical Trial With Blinded Endpoint Assessment of Prophylactic Rituximab for Reducing Clinically Significant EBV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Yang Donglin
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 9, 2026
Completion date
July 9, 2027
Enrollment
168 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic stem cell transplantation, clinically significant ebv dnaemia, epstein-barr virus reactivation